IBRX - ImmunityBio

-

$undefined

N/A

(N/A)

ImmunityBio NASDAQ:IBRX NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.

Location: 3530 John Hopkins Ct, California, 92121-1121, US | Website: immunitybio.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

4.69B

Cash

218M

Avg Qtr Burn

-102.5M

Short % of Float

31.17%

Insider Ownership

77.04%

Institutional Own.

9.13%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Anktiva (N-803) + BCG Details
Bladder cancer, Cancer

Approved

Quarterly sales

PD-L1 t-haNK Details
Pancreatic cancer, Cancer

Phase 2/3

Update

Anktiva (N-803) + checkpoint inhibitors Details
Non-small cell lung carcinoma, Cancer, Solid tumor/s

Phase 2

Update

Anktiva (N-803) + AdHER2DC Details
Cancer, Solid tumor/s, Endometrial cancer

Phase 1/2

Initiation

CAR-NK / CD19 t-haNK Details
Cancer, Non-Hodgkin lymphoma

Phase 1

Data readout

hAd5-COVID-19 Details
Vaccine, COVID-19

Failed

Discontinued

N-803 (Anktiva), haNK and Avelumab Details
Metastatic merkel cell carcinoma, Insomnia, Mood disorders, Liver transplant, Cancer

Failed

Discontinued